Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Dai, Liping ^a   Li, Jitian ^a   Ortega, Rosalia ^a   Qian, Wei ^a   Casiano, Carlos A ^b   Zhang, Jian Ying ^a  

^a UNIVERSITY OF TEXAS AT EL PASO   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLIN B1; LENS EPITHELIUM DERIVED GROWTH FACTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN MDM2; PROTEIN P53; RALA PROTEIN; SURVIVIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CCNB1 PROTEIN, HUMAN; TUMOR MARKER;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; AUTOIMMUNITY; BLOOD; CASE CONTROL STUDY; EARLY DIAGNOSIS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; PROSTATIC NEOPLASMS;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; AUTOIMMUNITY; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CYCLIN B1; EARLY DIAGNOSIS; GENE EXPRESSION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 84900328650     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/827827     Document Type: Article

References (48)

1. Siegel R., Ma J., Zou Z., Jemal A., Cancer statistics, 2014. CA: A Cancer Journal for Clinicians 2014 64 1 9 29 10.3322/caac.21208
2. Chornokur G., Dalton K., Borysova M. E., Kumar N. B., Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 2011 71 9 985 997 2-s2.0-79955597996 10.1002/pros.21314
3. Culp S., Porter M., The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. British Journal of Urology International 2009 104 10 1457 1461 2-s2.0-72349095455 10.1111/j.1464-410X.2009.08646.x
4. Caire A. A., Sun L., Polascik T. J., Albala D. M., Moul J. W., Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans. British Journal of Urology International 2010 106 8 1157 1160 2-s2.0-77957581088 10.1111/j.1464-410X.2010. 09340.x
5. Robinson J. G., Hodges E. A., Davison J., Prostate-specific antigen screening: a critical review of current research and guidelines. Journal of the American Association of Nurse Practitioners 2014 10.1002/2327-6924.12094
6. Obort A. S., Ajadi M. B., Akinloye O., Prostate-specific antigen: any successor in sight? Review in Urology 2013 15 3 97 107
7. Anderson K. S., LaBaer J., The sentinel within: exploiting the immune system for cancer biomarkers. Journal of Proteome Research 2005 4 4 1123 1133 2-s2.0-23944522808 10.1021/pr0500814 (Pubitemid 41208670)
8. Zaenker P., Ziman M. R., Serologic autoantibodies as diagnostic cancer biomarkers-a review. Cancer Epidemiology, Biomarkers & Prevention 2013 22 12 2161 2181 10.1158/1055-9965.EPI-13-0621
9. Niméus-Malmström E., Koliadi A., Ahlin C., Holmqvist M., Holmberg L., Amini R.-M., Jirström K., Wärnberg F., Blomqvist C., Fernö M., Fjällskog M.-L., Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort. International Journal of Cancer 2010 127 4 961 967 2-s2.0-77954737040 10.1002/ijc.25091
10. Murakami H., Furihata M., Ohtsuki Y., Ogoshi S., Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma. Virchows Archiv 1999 434 2 153 158 2-s2.0-0033044020 10.1007/s004280050319 (Pubitemid 29184993)
11. Soria J.-C., Jang S. J., Khuri F. R., Hassan K., Liu D., Hong W. K., Mao L., Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Research 2000 60 15 4000 4004 2-s2.0-0033870724 (Pubitemid 30636572)
12. Begnami M. D., Fregnani J. H., Nonogaki S., Soares F. A., Evaluation of cell cycle protein expression in gastric cancer: cyclin B1 expression and its prognostic implication. Human Pathology 2010 41 8 1120 1127 2-s2.0-77955081225 10.1016/j.humpath.2010.01.007
13. Calvisi D. F., Simile M. M., Ladu S., Frau M., Evert M., Tomasi M. L., Demartis M. I., Daino L., Seddaiu M. A., Brozzetti S., Feo F., Pascale R. M., Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53. Hepatology 2011 53 4 1226 1236 2-s2.0-79953737159 10.1002/hep.24174
14. Covini G., Chan E. K. L., Nishioka M., Morshed S. A., Reed S. I., Tan E. M., Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology 1997 25 1 75 80 2-s2.0-0031021286 (Pubitemid 27014988)
15. Yu Y., Zhang Y., Guan W., Androgen receptor promotes the oncogenic function of overexpressed Jagged1 in prostate cancer by enhancing cyclin B1 expression via Akt phosphorylation. Molecular Cancer Research 2014 10.1158/1541-7786.MCR-13-0545
16. Pandey J. P., Namboodiri A. M., Kistner-Griffin E., A genetic variant of Fc γ RIIIa is strongly associatedwith humoral immunity to cyclin B1 in African American patients with prostate cancer. Immunogenetics 2013 65 2 91 96 10.1007/s00251-012-0660-y
17. Stephan C., Jung K., Lein M., Diamandis E. P., PSA and other tissue kallikreins for prostate cancer detection. European Journal of Cancer 2007 43 13 1918 1926 2-s2.0-34548066226 10.1016/j.ejca.2007.06.006 (Pubitemid 47287733)
18. Zhang J.-Y., Megliorino R., Peng X.-X., Tan E. M., Chen Y., Chan E. K. L., Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. Journal of Hepatology 2007 46 1 107 114 2-s2.0-34548606659 10.1016/j.jhep.2006.08.010 (Pubitemid 44827418)
19. Shi F.-D., Zhang J.-Y., Liu D., Rearden A., Elliot M., Nachtsheim D., Daniels T., Casiano C. A., Heeb M. J., Chan E. K. L., Tan E. M., Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 2005 63 3 252 258 2-s2.0-20244389381 10.1002/pros.20181 (Pubitemid 40571059)
20. Imai H., Chan E. K. L., Kiyosawa K., Fu X.-D., Tan E. M., Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. The Journal of Clinical Investigation 1993 92 5 2419 2426 2-s2.0-0027437244 (Pubitemid 23333550)
21. Zhang J.-Y., Casiano C. A., Peng X.-X., Koziol J. A., Chan E. K. L., Tan E. M., Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiology, Biomarkers & Prevention 2003 12 2 136 143 2-s2.0-12244249834 (Pubitemid 36194003)
22. Tan E. M., Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Advances in Immunology 1989 44 93 151 2-s2.0-0024518559 (Pubitemid 19090837)
23. Nielsen J., Christiansen J., Lykke-Andersen J., Johnsen A. H., Wewer U. M., Nielsen F. C., A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Molecular and Cellular Biology 1999 19 2 1262 1270 2-s2.0-0032908981 (Pubitemid 29046868)
24. Junttila M. R., Puustinen P., Niemelä M., Ahola R., Arnold H., Böttzauw T., Ala-aho R., Nielsen C., Ivaska J., Taya Y., Lu S.-L., Lin S., Chan E. K. L., Wang X.-J., Grènman R., Kast J., Kallunki T., Sears R., Kähäri V.-M., Westermarck J., CIP2A inhibits PP2A in human malignancies. Cell 2007 130 1 51 62 2-s2.0-34447283580 10.1016/j.cell.2007.04. 044 (Pubitemid 47039258)
25. Sablina A. A., Chen W., Arroyo J. D., Corral L., Hector M., Bulmer S. E., DeCaprio J. A., Hahn W. C., The tumor suppressor PP2A A β regulates the RalA GTPase. Cell 2007 129 5 969 982 2-s2.0-34249291096 10.1016/j.cell.2007.03. 047 (Pubitemid 46813152)
26. Westermarck J., Regulation of transcription factor function by targeted protein degradation: an overview focusing on p53, c-Myc, and c-Jun. Methods in Molecular Biology 2010 647 31 36 2-s2.0-78349246810
27. Johnson M. E., Howerth E. W., Survivin: a bifunctional inhibitor of apoptosis protein. Veterinary Pathology 2004 41 6 599 607 2-s2.0-9644260590 10.1354/vp.41-6-599 (Pubitemid 39573750)
28. Aitken A., 14-3-3 proteins: a historic overview. Seminars in Cancer Biology 2006 16 3 162 172 2-s2.0-33646926129 10.1016/j.semcancer.2006.03.005 (Pubitemid 43796128)
29. Rayburn E., Zhang R., He J., Wang H., MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Current Cancer Drug Targets 2005 5 1 27 41 2-s2.0-14644403700 10.2174/1568009053332636 (Pubitemid 40321798)
30. Kruse J.-P., Gu W., Modes of p53 regulation. Cell 2009 137 4 609 622 2-s2.0-65549120715 10.1016/j.cell.2009.04.050
31. Sherr C. J., The INK4a/ARF network in tumour suppression. Nature Reviews Molecular Cell Biology 2001 2 10 731 737 2-s2.0-0035487104 10.1038/35096061 (Pubitemid 33679835)
32. Li Z., Hann S. R., The Myc-nucleophosmin-ARF network: a complex web unveiled. Cell Cycle 2009 8 17 2703 2707 2-s2.0-69749086004
33. Daniels T., Zhang J., Gutierrez I., Elliot M. L., Yamada B., Heeb M. J., Sheets S. M., Wu X., Casiano C. A., Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate 2005 62 1 14 26 2-s2.0-10144237224 10.1002/pros.20112 (Pubitemid 39614289)
34. Tan E. M., Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. The Journal of Clinical Investigation 2001 108 10 1411 1415 2-s2.0-0035189977 10.1172/JCI200114451 (Pubitemid 33091976)
35. Zeliadt S. B., Hoffman R. M., Etzioni R., Gore J. L., Kessler L. G., Lin D. W., Influence of publication of US and European prostate cancer screening trials on PSA testing practices. Journal of the National Cancer Institute 2011 103 6 520 523 2-s2.0-79952846678 10.1093/jnci/djr007
36. Xie C., Kim H. J., Haw J. G., Kalbasi A., Gardner B. K., Li G., Rao J.-Y., Chia D., Liong M., Punzalan R. R., Marks L. S., Pantuck A. J., de la Taille A., Wang G., Mukouyama H., Zeng G., A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. Journal of Translational Medicine 2011 9, article 43 2-s2.0-79955105862 10.1186/1479-5876-9-43
37. Chen H., Werner S., Tao S., Zornig I., Brenner H., Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer. Cancer Letters 2014 346 2 178 187 10.1016/j.canlet.2014.01.007
38. Werner S., Chen H., Tao S., Brenner H., Systematic review: serum autoantibodies in the early detection of gastric cancer. International Journal of Cancer 2014 10.1002/ijc.28807
39. Weng L., Du J., Zhou Q., Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection. Molecular Cancer 2012 11, article 39 10.1186/1476-4598-11-39
40. Aaltonen K., Amini R.-M., Heikkilä P., Aittomäki K., Tamminen A., Nevanlinna H., Blomqvist C., High cyclin B1 expression is associated with poor survival in breast cancer. British Journal of Cancer 2009 100 7 1055 1060 2-s2.0-63949088181 10.1038/sj.bjc.6604874
41. Tan E. M., Zhang J., Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunological Reviews 2008 222 1 328 340 2-s2.0-41149178259 10.1111/j.1600-065X.2008.00611.x (Pubitemid 351430373)
42. Ritch C. R., Morrison B. F., Hruby G., Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison. British Journal of Urology International 2013 111 4 E186 E190 10.1111/j.1464-410X.2012.11540.x
43. Casiano C. A., Mediavilla-Varela M., Tan E. M., Tumor-associated antigen arrays for the serological diagnosis of cancer. Molecular and Cellular Proteomics 2006 5 10 1745 1759 2-s2.0-33750605893 10.1074/mcp.R600010-MCP200 (Pubitemid 44688185)
44. Wang X., Yu J., Sreekumar A., Autoantibody signatures in prostate cancer. The New England Journal of Medicine 2005 353 12 1224 1235 10.1056/NEJMoa051931 (Pubitemid 41345944)
45. Dai L., Lei N., Liu M., Zhang J. Y., Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC). Experimental Hematology & Oncology 2013 2 1, article 15 10.1186/2162-3619-2-15
46. Koziol J. A., Zhang J.-Y., Casiano C. A., Peng X.-X., Shi F.-D., Feng A. C., Chan E. K. L., Tan E. M., Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clinical Cancer Research 2003 9 14 5120 5126 2-s2.0-0242610432 (Pubitemid 37413560)
47. Ye H., Sun C., Ren P., Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Oncology Letters 2013 5 2 663 668
48. Chen Y., Zhou Y., Qiu S., Wang K., Liu S., Peng X.-X., Li J., Tan E. M., Zhang J.-Y., Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Letters 2010 289 1 32 39 2-s2.0-75949088039 10.1016/j.canlet.2009.07.016